Medtronic plc Earnings Recaps
Q4 2026
Jun 5, 2026
Shares rallied 11.1% as investors responded positively to strong organic revenue growth and robust execution in high-growth platforms, particularly in Cardiac Ablation Solutions (CAS) and advances in surgical robotics.
Key takeaways
- Q4 revenue reached $9.8 billion, up 6.6% organically and 9.9% reported, marking the strongest top-line performance in a decade.
- Adjusted EPS was $1.55 in Q4 and $5.53 for fiscal year 2026, reflecting disciplined operational execution.
- CAS grew 78% globally, driven by PFA’s 145% growth and an expanded U.S. installed base up 40% sequentially.
- Symplicity, the minimally invasive hypertension treatment, is annualizing at $100 million with growing physician adoption and procedure volumes.
- Hugo surgical robotics procedures grew 2 to 3 times faster than the market, with recent U.S. rollout and promising early clinical feedback.
Q3 2026
Feb 17, 2026
Medtronic demonstrated robust performance in its latest quarter, reporting an 11% year-over-year revenue growth, driven significantly by innovation in cardiovascular and neurological segments.
Key takeaways
- The Cardiovascular portfolio achieved 11% revenue growth, with CAS growing a staggering 80% year-over-year.
- The Hugo robot received FDA clearance for urologic procedures, marking a significant step in its U.S. market entry with early installations at hospitals like Cleveland Clinic.
- The introduction of Altaviva for urge urinary incontinence has garnered strong initial interest, reflecting effective direct-to-consumer marketing efforts.
- Stealth AXiS surgical system has received FDA clearance, enhancing Medtronic's capabilities in spinal procedures and expanding their leadership in surgical navigation.
- Continued focus on innovation is expected to drive sustained growth across high-need categories, with new product launches in the pipeline.